Antibody diversity in IVIG: Therapeutic opportunities for novel immunotherapeutic drugs
Significant progress has been made in the elucidation of human antibody repertoires. Furthermore, non-canonical functions of antibodies have been identified that reach beyond classical functions linked to protection from pathogens. Polyclonal immunoglobulin preparations such as IVIG and SCIG represe...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2023-03-01
|
| Series: | Frontiers in Immunology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fimmu.2023.1166821/full |
| _version_ | 1797857821095624704 |
|---|---|
| author | Stephan von Gunten Christoph Schneider Lejla Imamovic Guy Gorochov |
| author_facet | Stephan von Gunten Christoph Schneider Lejla Imamovic Guy Gorochov |
| author_sort | Stephan von Gunten |
| collection | DOAJ |
| description | Significant progress has been made in the elucidation of human antibody repertoires. Furthermore, non-canonical functions of antibodies have been identified that reach beyond classical functions linked to protection from pathogens. Polyclonal immunoglobulin preparations such as IVIG and SCIG represent the IgG repertoire of the donor population and will likely remain the cornerstone of antibody replacement therapy in immunodeficiencies. However, novel evidence suggests that pooled IgA might promote orthobiotic microbial colonization in gut dysbiosis linked to mucosal IgA immunodeficiency. Plasma-derived polyclonal IgG and IgA exhibit immunoregulatory effects by a diversity of different mechanisms, which have inspired the development of novel drugs. Here we highlight recent insights into IgG and IgA repertoires and discuss potential implications for polyclonal immunoglobulin therapy and inspired drugs. |
| first_indexed | 2024-04-09T21:03:01Z |
| format | Article |
| id | doaj.art-5d056e09d20947eeb7d7f2d3a920703b |
| institution | Directory Open Access Journal |
| issn | 1664-3224 |
| language | English |
| last_indexed | 2024-04-09T21:03:01Z |
| publishDate | 2023-03-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Immunology |
| spelling | doaj.art-5d056e09d20947eeb7d7f2d3a920703b2023-03-29T06:15:23ZengFrontiers Media S.A.Frontiers in Immunology1664-32242023-03-011410.3389/fimmu.2023.11668211166821Antibody diversity in IVIG: Therapeutic opportunities for novel immunotherapeutic drugsStephan von Gunten0Christoph Schneider1Lejla Imamovic2Guy Gorochov3Institute of Pharmacology, University of Bern, Bern, SwitzerlandInstitute of Pharmacology, University of Bern, Bern, SwitzerlandSorbonne Université, Inserm, Assistance Publique Hôpitaux de Paris (AP-HP), Pitié-Salpêtrière Hospital, Paris, FranceSorbonne Université, Inserm, Assistance Publique Hôpitaux de Paris (AP-HP), Pitié-Salpêtrière Hospital, Paris, FranceSignificant progress has been made in the elucidation of human antibody repertoires. Furthermore, non-canonical functions of antibodies have been identified that reach beyond classical functions linked to protection from pathogens. Polyclonal immunoglobulin preparations such as IVIG and SCIG represent the IgG repertoire of the donor population and will likely remain the cornerstone of antibody replacement therapy in immunodeficiencies. However, novel evidence suggests that pooled IgA might promote orthobiotic microbial colonization in gut dysbiosis linked to mucosal IgA immunodeficiency. Plasma-derived polyclonal IgG and IgA exhibit immunoregulatory effects by a diversity of different mechanisms, which have inspired the development of novel drugs. Here we highlight recent insights into IgG and IgA repertoires and discuss potential implications for polyclonal immunoglobulin therapy and inspired drugs.https://www.frontiersin.org/articles/10.3389/fimmu.2023.1166821/fullantibodiesintravenous immune globulin (IVIg)subcutaneous immunoglobulinIgAimmunotherapy |
| spellingShingle | Stephan von Gunten Christoph Schneider Lejla Imamovic Guy Gorochov Antibody diversity in IVIG: Therapeutic opportunities for novel immunotherapeutic drugs Frontiers in Immunology antibodies intravenous immune globulin (IVIg) subcutaneous immunoglobulin IgA immunotherapy |
| title | Antibody diversity in IVIG: Therapeutic opportunities for novel immunotherapeutic drugs |
| title_full | Antibody diversity in IVIG: Therapeutic opportunities for novel immunotherapeutic drugs |
| title_fullStr | Antibody diversity in IVIG: Therapeutic opportunities for novel immunotherapeutic drugs |
| title_full_unstemmed | Antibody diversity in IVIG: Therapeutic opportunities for novel immunotherapeutic drugs |
| title_short | Antibody diversity in IVIG: Therapeutic opportunities for novel immunotherapeutic drugs |
| title_sort | antibody diversity in ivig therapeutic opportunities for novel immunotherapeutic drugs |
| topic | antibodies intravenous immune globulin (IVIg) subcutaneous immunoglobulin IgA immunotherapy |
| url | https://www.frontiersin.org/articles/10.3389/fimmu.2023.1166821/full |
| work_keys_str_mv | AT stephanvongunten antibodydiversityinivigtherapeuticopportunitiesfornovelimmunotherapeuticdrugs AT christophschneider antibodydiversityinivigtherapeuticopportunitiesfornovelimmunotherapeuticdrugs AT lejlaimamovic antibodydiversityinivigtherapeuticopportunitiesfornovelimmunotherapeuticdrugs AT guygorochov antibodydiversityinivigtherapeuticopportunitiesfornovelimmunotherapeuticdrugs |